Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-12-09
2010-11-09
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S141100, C424S145100
Reexamination Certificate
active
07829085
ABSTRACT:
The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is a partially inhibitory antibody of Factor VIII.
REFERENCES:
patent: 4451454 (1984-05-01), Wong
patent: 5545403 (1996-08-01), Page
patent: 5545404 (1996-08-01), Page
patent: 5545405 (1996-08-01), Page
patent: 5602015 (1997-02-01), Sudhir
patent: 5714350 (1998-02-01), Co et al.
patent: 5744446 (1998-04-01), Lollar et al.
patent: 6005091 (1999-12-01), Blackburn et al.
patent: 6210675 (2001-04-01), Highfield et al.
patent: 7067313 (2006-06-01), Jacquemin et al.
patent: 7214785 (2007-05-01), Nakashima et al.
patent: 2001/0018052 (2001-08-01), Feuerstein
patent: 2002/0182208 (2002-12-01), Page et al.
patent: 2003/0035799 (2003-02-01), Page et al.
patent: 2003/0175268 (2003-09-01), Saint-Remy et al.
patent: 2004/0120951 (2004-06-01), Nakashima et al.
patent: 2004/0228857 (2004-11-01), Page et al.
patent: 2006/0292149 (2006-12-01), Saint-Remy et al.
patent: 2008/0206254 (2008-08-01), Jacquemin et al.
patent: 0 822 255 (1998-02-01), None
patent: 1222929 (2002-07-01), None
patent: 1396539 (2004-03-01), None
patent: 1706079 (2006-10-01), None
patent: 1194528 (2007-03-01), None
patent: 1910420 (2008-04-01), None
patent: WO 97 26010 (1997-07-01), None
patent: WO 99/58680 (1999-11-01), None
patent: WO 01/04269 (2001-01-01), None
patent: WO 2005/016455 (2005-02-01), None
patent: WO 2005/046583 (2005-05-01), None
patent: WO 2007/017154 (2007-02-01), None
Fukui et al., Thromb. Res. 1981, 22;177-184.
Price et al., Anaesthesia, 2004, 59:483-492.
Janeway et al., Immunobiology, third edition, Garland Press, 1997, pp. 3:7-3:11.
Amit et al., 1986, Science 233:747-753.
Rudikoff et al. PNAS USA, 1982, 79:1979-1983.
Janeway et al., Immunobiology, sixth edition, Garland Press, 2005, pp. 379-381.
Peerlinck et al., Blood, 1999, 93:2267-2273.
Palmer et al., Vox Sang, 1997, 72:148-161.
Portolano et al., J. Immunol., 1993, 150:880-887.
Wright et al., EMBO J., 10:2717-2723.
Endo et al., Mol. Immunol., 1995, 32:931-940.
Database BIOSIS (Accession No. PREV200400181293), Jacquemin et al., “Glycosylation of a Type 2 Factor VIII Inhibitor determines it Maximum Level of FVIII Inhibition,” Nov. 16, 2003 (XP-002314129).
International Preliminary Report on Patentability (PCT/BE2004/000118) (Dec. 2, 2005).
International Search Report (PCT/BE2004/000118) (mailed Feb. 2, 2005).
Kallas et al., “Epitope Specificity of Anti-FVIII Antibodies During Immune Tolerance Therapy with Factor VIII Preparation Containing von Willebrand Factor,”Thrombosis Research107:291-302 (2002).
Kato et al., “Activity Enhancement of a Lung Cancer-Associated Human Monoclonal Antibody HB4C5 byN-Deglycosylation,”Hum. Antibod. Hybridomas4:9-14 (1993).
Khurana et al., “The Variable Domain Glycosylation in a Monoclonal Antibody Specific to GnRH Modulates Antigen Binding,” Biochem. Biophys. Res. Comm. 234:465-469 (1997).
Response to Written Opinion dated Feb. 2, 2005 (PCT/BE2004/000118) (Apr. 22, 2005).
Sato et al., “Humanization of an Anti-Human IL-6 Mouse Monoclonal Antibody Glycosylated in its Heavy Chain Variable Region,” Hum. Antibod. Hybridomas 7:175-183 (1996).
Singh et al., “Antithrombotic Effects of Controlled Inhibition of Factor VIII with a Partially Inhibitory Human Monoclonal Antibody in a Murine Vena Cava Thrombosis Model,”Blood99:3235-3240 (2002).
Wright et al., “Antibody Variable Region Glycosylation: Position Effects on Antigen Binding and Carbohydrate Structure,”EMBO J. 10:2717-2723 (1991).
Written Opinion of the International Searching Authority (PCT/BE2004/000118) (Feb. 2, 2005).
Battle et al., “Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor FVIII interaction.”Ann Hematol, 75: 111-115 (1997).
Gawryl et al., “Inactivation of factor VIII coagulant activity by two different types of human antibodies.”Blood, 60: 1103-1109 (1982).
Ingerslev et al., “Applications of immunoperoxidase techniques in specificity testing of monoclonal antibodies (Mabs) against von Willebrand factor (vWF).”Clinica Chimica Acta, 174:65-82 (1988).
Jacquemin et al., “A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.”Blood95: 156-163 (2000).
Jacquemin et al., “Mechanism and kinetics of factor VIII inactivation: Study with a IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor.”Blood92: 496-506 (1998).
Ly et al., “Characterization of an antibody to factor VIII in a patient with acquired hemophilia with circulating immune complexes.”Scand J of Haematol28: 132-140 (1982).
Foster et al., “An Immunogenic Region within Residues Val1670-Glu1684of the Factor VIII Light Chain Induces Antibodies Which Inhibit Binding Factor VIII to von Willebrand Factor,”J. Biol. Chem. 263:5230-5234 (1988).
Fulcher et al., “Human Factor VIII Procoagulant Protein: Monoclonal Antibodies Define Precursor-Product Relationships and Functional Epitopes,”J. Clin. Invest. 76:117-124 (1985).
Precup et al., “A Monoclonal Antibody to Factor VIII Inhibits von Willebrand Factor Binding and Thrombin Cleavage,”Blood77(9):1929-1936 (1991).
Communication mailed Oct. 15, 2007 in Canadian Patent Application No. 2,381,125.
Translation of Notice of Grounds of Rejection mailed Oct. 30, 2007 in Japanese Patent Application No. 509473/2001.
Translation of Final Decision for Rejection mailed Apr. 8, 2008 in Japanese Patent Application No. 509473/2001.
Davies et al., “Affinity Improvement of Single Antibody VH Domains: Residues in all Three Hypervariable Regions Affect Antigen Binding,”Immunotechnology2:169-179, 1996.
Gilles et al., “Mutation Arg2150-His in the Factor VIII C1 Domain Alters the Binding of Factor VIII to von Willebrand Factor and is Responsible for a Mild Hemophilia A Phenotype,”Blood92(Suppl. 1, Part 1-2):710A, 1998. Abstract 2919.
Healey et al., “Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII,”J. Biol. Chem. 270(24):14505-14509, 1995.
Holt et al., “Domain Antibodies: Proteins for Therapy,”Trends Biotechnol. 21(11):484-490, 2003.
Lenting et al., “Identification of a Binding Site for Blood Coagulation Factor IXa on the Light Chain of Human Factor FVIII,”J. Biol. Chem. 269(10):7150-7155, 1994.
Scandella et al., “Localization of Epitopes for Human Factor VIII Inhibitor Antibodies by Immunoblotting and Antibody Neutralization,”Blood74(5):1618-1626, 1989.
Stoilova-McPhie et al., “3-Dimensional Structure of Membrane-Bound Coagulation Factor VIII: Modeling of the Factor VIII Heterodimer within a 3-Dimensional Density Map Derived by Electron Crystallography,”Blood99(4):1215-1223, 2002.
Van den Brink et al., “Molecular Analysis of Human Anti-Factor VIII Antibodies by V Gene Phage Display Identifies a New Epitope in the Acidic Region Following the A2 Domain,”Blood96(2):540-545, 2000.
Communication in European Patent Application No. 00949329.7-2402, mailed Jul. 16, 2003.
Response to Communication in European Patent Application No. 00949329.7-2402, mailed Dec. 26, 2003.
Communication in European Patent Application No. 00949329.7-2402, mailed Apr. 12, 2005.
Response to Communication in European Patent Application No. 00949329.7-2402, mailed Apr. 28, 2005.
Further Response to Communication in European Patent Application No. 00949329.7-2402, mailed Jan. 13, 2006.
Communication in European Patent Application No. 06776526.3-2402, mailed May 7, 2008.
International Search Report for PCT/EP2006/007564, completed Jan. 22, 2007.
International Search Report for PCT
Jacquemin Marc G.
Saint-Remy Jean-Marie R.
Clark & Elbing LLP
Life Sciences Research Partners VZW
Szperka Michael
LandOfFree
Methods of treating hemostasis disorders using antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating hemostasis disorders using antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating hemostasis disorders using antibodies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4249998